Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
暂无分享,去创建一个
S. Lim | M. Burroughs | Y. Kim | J. Heo | Lai Wei | J. Jia | W. Xie | J. Hou | H. Kalluri | Guiqiang Wang | Q. Xie | N. Mobashery | Wei Liu | L. Fredrick | R. Tripathi | Wenjing Lu | A. Asatryan | Ming-xiang Zhang | N. Alami | Preethi Krishnan